Home > Products > OBM

Quick Detection and Intelligent Identification of Cerebral Dysfunction

in Neonates Including Premature Infants, Offering Easily Interpretable

Reference for Optimal Therapy

Solutions

With the intelligent amplitude-integrated EEG (aEEG) acquisition and processing technology that has been proven clinically at home and abroad, Natus® new generation of OBM can have the original EEG filtered, corrected and time compressed and then use the OBM patented technology and functions to generate the EEG activity trends that can be easily interpreted by medical staff in neonatology department and also the automatic identification, analysis and evaluation reports. It has great clinical value in evaluation of EEG background activities, correct identification of convulsions, early detection of HIE and other diseases, neonatal cerebral injury screening, drug effect monitoring, and prognosis prediction and evaluation, so it has been widely used in neonatal ICUs abroad for its simplicity, usability, suitability and other features.
NICU Indications

Infant patients with cerebral injury:

hypoxic-ischemic encephalopathy, cerebral infarction, PVL/periventricular hemorrhage, intracranial hemorrhage, central nervous system cancer causing infection, brain structural abnormalities including structural abnormalities (cerebral gyrus/cerebrovascular/deep nuclei) and tumor space occupying, neonatal premature epilepsy or epileptic encephalopathy, as well as intrapartum or postpartum cranial trauma or surgery.

High-risk infants with cerebral injury:

hypoxic-ischemic encephalopathy, cerebral infarction, PVL/periventricular hemorrhage, intracranial hemorrhage, central nervous system cancer causing infection, brain structural abnormalities including structural abnormalities (cerebral gyrus/cerebrovascular/deep nuclei) and tumor space occupying, neonatal premature epilepsy or epileptic encephalopathy, as well as intrapartum or postpartum cranial trauma or surgery.

Evaluation of neonatal brain development; and detection of neonatal convulsion and suspected convulsion seizures.

Evaluation of therapeutic effects of cerebral injury, such as mild hypothermia therapy and anticonvulsant drugs for arresting convulsion.

Approved by U.S. FDA 510K and Specific to Premature Infants and Neonates

01.Measuring

02.Marking

03.Cleaning

04.Applying electrodes

05.Fixing

Designed for medical staff in neonatology department, easy to learn and use

Automatic Classification of EEG Background Activities

The patented BPC EEG background activity classification technology can intelligently analyze and automatically classify the collected aEEG background activity patterns based on the five-level classification criterion, thus bringing about the following clinical benefits:

  • Fast and accurate abnormal warning
  • Objective reference of intervention measures such as mild hypothermia therapy
  • Accurate evaluation of therapy and prognosis

Intelligent Identification of Convulsion

Neonatal convulsion is clinically atypical and will be manifested sub-clinically, so it is difficult to be found without special monitoring means. Neonatal convulsion is an important manifestation of central nervous system dysfunction. Neonatal convulsion occurs much higher than any period thereafter and 80%1 occurs in the postnatal week, so the monitoring of neonatal convulsion and the evaluation of its therapeutic effect are very important.
RecogniZe technology for intelligent identification of neonatal convulsion can automatically identify convulsion seizure and mark the active position, which is clear at a glance. Also, the EEGs can be extracted on the same screen for review. Identify convulsion with little effort from now on.

Synchronous Continuous Impedance Test

OBM’s synchronous continuous impedance test function for neonate monitoring displays the impedance state of electrodes (poor contact or falling-off) with icons in real time to ensure high-quality signal acquisition.

1Ma Simin, Yang Lin and Zhou Wenhao. Progress in Diagnosis and Treatment of Neonatal Convulsion [J]. Chinese Journal of Evidence-based Pediatrics, 2015, 10 (2).

CFMSightTM Grayscale Enhanced Display

The graphical representation is normal when CFMSightTM is not used.


The same graph demonstrates burst suppression and restores the true EEG state upon the use of CFMSightTM grayscale enhanced display function.

Flexible and Practical Data Management System

Easy for Exchange and Collaboration

OBM data management system facilitates data recording, printing and transmission. It supports remote browsing and consultation, allowing the computer to browse the ongoing or saved OBM bedside monitoring records from any remote location, and to remotely make commentary or event marking, which simplifies the management of clinical consultation.

Marking in different colors can discriminate bedside markings or remote markings made by software.

User-defined timestamped markings are used to track the management of treatment, making the clinical assessment process more efficient and easier for mutual cooperation.

American Natus Medical Incorporated (Natus), founded in 1989, is a multinational manufacturer that focuses on promoting and developing neonatal medicine and provides continuously advancing medical equipment and technology for clinical use. Natus offers products covering neurology, sleep, hearing and balanced development. The company's mission is to improve medical quality and prognosis of infant patients through iterative screening, diagnosis and therapy protocols.
Sense Medical is committed to the development of emerging medical technologies. It continuously introduces the non-invasive, convenient and accurate foreign technologies such as neonatal eye disease screening and diagnosis, ETCO rapid detection for neonatal hemolysis, and emergency and critical care monitoring into China, so as to protect the children's health and happiness through scientific medical technologies and solutions. It is an important partner of Natus Medical in China.
×